This paper is a wonderful summary of the various trials, how vasculitis is defined, the role of ANCA, etc. The primary grouping of syndromes is clinical, and this determines the various trial designs. The study compares the ability to substitute MTX for CYC, hopefully reducing toxicity. In patients with mild renal disease, studies ability to substitute AZA for CYC after 3 months. The above are the standard arms.
Trial compares adjuvant IVIg or trimethoprim-sulfamethoxasole, or both.